FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255172204> ?p ?o ?g. }

• W4255172204 abstract "Abstract Background Febrile neutropenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimized administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematologic patients with FN. Methods A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 minutes) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematologic patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes." @default.
• W4255172204 created "2022-05-12" @default.
• W4255172204 creator A5000169882 @default.
• W4255172204 creator A5000665386 @default.
• W4255172204 creator A5003306972 @default.
• W4255172204 creator A5016132321 @default.
• W4255172204 creator A5020455030 @default.
• W4255172204 creator A5025521012 @default.
• W4255172204 creator A5028199476 @default.
• W4255172204 creator A5048315302 @default.
• W4255172204 creator A5053444946 @default.
• W4255172204 creator A5054374372 @default.
• W4255172204 creator A5055475898 @default.
• W4255172204 creator A5069417979 @default.
• W4255172204 creator A5077430940 @default.
• W4255172204 creator A5078199034 @default.
• W4255172204 creator A5081446167 @default.
• W4255172204 creator A5083540033 @default.
• W4255172204 creator A5084224807 @default.
• W4255172204 creator A5085146096 @default.
• W4255172204 creator A5087960692 @default.
• W4255172204 date "2020-04-10" @default.
• W4255172204 modified "2023-10-18" @default.
• W4255172204 title "Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)" @default.
• W4255172204 doi "https://doi.org/10.21203/rs.2.24695/v2" @default.
• W4255172204 hasPublicationYear "2020" @default.
• W4255172204 type Work @default.
• W4255172204 citedByCount "0" @default.
• W4255172204 crossrefType "posted-content" @default.
• W4255172204 hasAuthorship W4255172204A5000169882 @default.
• W4255172204 hasAuthorship W4255172204A5000665386 @default.
• W4255172204 hasAuthorship W4255172204A5003306972 @default.
• W4255172204 hasAuthorship W4255172204A5016132321 @default.
• W4255172204 hasAuthorship W4255172204A5020455030 @default.
• W4255172204 hasAuthorship W4255172204A5025521012 @default.
• W4255172204 hasAuthorship W4255172204A5028199476 @default.
• W4255172204 hasAuthorship W4255172204A5048315302 @default.
• W4255172204 hasAuthorship W4255172204A5053444946 @default.
• W4255172204 hasAuthorship W4255172204A5054374372 @default.
• W4255172204 hasAuthorship W4255172204A5055475898 @default.
• W4255172204 hasAuthorship W4255172204A5069417979 @default.
• W4255172204 hasAuthorship W4255172204A5077430940 @default.
• W4255172204 hasAuthorship W4255172204A5078199034 @default.
• W4255172204 hasAuthorship W4255172204A5081446167 @default.
• W4255172204 hasAuthorship W4255172204A5083540033 @default.
• W4255172204 hasAuthorship W4255172204A5084224807 @default.
• W4255172204 hasAuthorship W4255172204A5085146096 @default.
• W4255172204 hasAuthorship W4255172204A5087960692 @default.
• W4255172204 hasBestOaLocation W42551722041 @default.
• W4255172204 hasConcept C111113717 @default.
• W4255172204 hasConcept C112705442 @default.
• W4255172204 hasConcept C126322002 @default.
• W4255172204 hasConcept C177713679 @default.
• W4255172204 hasConcept C203092338 @default.
• W4255172204 hasConcept C2776694085 @default.
• W4255172204 hasConcept C2777050379 @default.
• W4255172204 hasConcept C2777063308 @default.
• W4255172204 hasConcept C2777288759 @default.
• W4255172204 hasConcept C2777637488 @default.
• W4255172204 hasConcept C2777858937 @default.
• W4255172204 hasConcept C2778193466 @default.
• W4255172204 hasConcept C2778266534 @default.
• W4255172204 hasConcept C2778850193 @default.
• W4255172204 hasConcept C2779375183 @default.
• W4255172204 hasConcept C2779631663 @default.
• W4255172204 hasConcept C2908647359 @default.
• W4255172204 hasConcept C501593827 @default.
• W4255172204 hasConcept C523546767 @default.
• W4255172204 hasConcept C535046627 @default.
• W4255172204 hasConcept C54355233 @default.
• W4255172204 hasConcept C71924100 @default.
• W4255172204 hasConcept C86803240 @default.
• W4255172204 hasConcept C89423630 @default.
• W4255172204 hasConcept C94665300 @default.
• W4255172204 hasConcept C99454951 @default.
• W4255172204 hasConceptScore W4255172204C111113717 @default.
• W4255172204 hasConceptScore W4255172204C112705442 @default.
• W4255172204 hasConceptScore W4255172204C126322002 @default.
• W4255172204 hasConceptScore W4255172204C177713679 @default.
• W4255172204 hasConceptScore W4255172204C203092338 @default.
• W4255172204 hasConceptScore W4255172204C2776694085 @default.
• W4255172204 hasConceptScore W4255172204C2777050379 @default.
• W4255172204 hasConceptScore W4255172204C2777063308 @default.
• W4255172204 hasConceptScore W4255172204C2777288759 @default.
• W4255172204 hasConceptScore W4255172204C2777637488 @default.
• W4255172204 hasConceptScore W4255172204C2777858937 @default.
• W4255172204 hasConceptScore W4255172204C2778193466 @default.
• W4255172204 hasConceptScore W4255172204C2778266534 @default.
• W4255172204 hasConceptScore W4255172204C2778850193 @default.
• W4255172204 hasConceptScore W4255172204C2779375183 @default.
• W4255172204 hasConceptScore W4255172204C2779631663 @default.
• W4255172204 hasConceptScore W4255172204C2908647359 @default.
• W4255172204 hasConceptScore W4255172204C501593827 @default.
• W4255172204 hasConceptScore W4255172204C523546767 @default.
• W4255172204 hasConceptScore W4255172204C535046627 @default.
• W4255172204 hasConceptScore W4255172204C54355233 @default.
• W4255172204 hasConceptScore W4255172204C71924100 @default.
• W4255172204 hasConceptScore W4255172204C86803240 @default.
• W4255172204 hasConceptScore W4255172204C89423630 @default.
• W4255172204 hasConceptScore W4255172204C94665300 @default.

• next